BioVersys AG is a privately held Swiss pharmaceutical company focusing on R&D of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation.
Cooperation possibilities
Partnering options for the co-development of TRIC molecules restoring the activity of approved antibiotics against severe hospital acquired bacterial infections. TRIC molecules have the ability to switch-off bacterial resistance.
- http://www.bioversys.com
- +41 61 633 22 50
- info@bioversys.com
- Marc Gitzinger
